Author Archives: David Melamed

Cure SMA to Host Annual Gala Virtually for First Time With Masquerade Party

Cure SMA, a nonprofit group supporting people with spinal muscular atrophy (SMA) and investing in SMA research, will host its first-ever virtual gala on Tuesday, Oct. 27, in an event titled Cure SMA Evening of Hope: A Virtual Masquerade. “It will be an evening celebrating innovation…

EU Approves EONIS System to Screen Newborns for SMA, Other Conditions

The EONIS system, a screening assay capable of simultaneously testing newborns for three genetic conditions, including spinal muscular atrophy (SMA), has received a CE marking from the European Commission for an in vitro device. The approval will allow its developer, PerkinElmer, to make the EONIS…

AveXis Now Known as Novartis Gene Therapies, Focus of Continuing Work

Two years after acquiring the gene therapy company AveXis, Novartis has renamed it Novartis Gene Therapies to underscore the potential value of developing such treatments for genetic diseases. This decision was based partly on the success of Zolgensma, originally developed by AveXis, as…

Cure SMA Offers Free Medical Alert Bracelet Kits to US Patients

Cure SMA has launched a new program to offer medical alert bracelets to spinal muscular atrophy (SMA) patients in the United States at no cost to the patient, according to a press release. Patients with a confirmed diagnosis of SMA are eligible for the bracelet program…